Not Tagged
Not Tagged
[]
dr. ardaman shergill #gi23 presents the argument to delay use of anti-egfr therapy1st line therapy mcrc based on limited clinical benefit (3-5 m os advantage) clinical toxicity financial toxicity ($$$) 
Gastrointestinal Oncologist, Physician Scientist & Mother CMO PanOncology Trials. Tweets are mine.